-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SYL-1801 in Wet (Neovascular / Exudative) Macular Degeneration
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SYL-1801 in Wet (Neovascular / Exudative) Macular Degeneration Drug Details: SYL-1801 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-0472 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MK-0472 in Solid Tumor Drug Details: MK-0472 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6314 in Asthma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RG-6314 in Asthma Drug Details:RG-6314 is under development for the treatment of asthma. The drug candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JNJ-4804 in Crohn’s Disease (Regional Enteritis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JNJ-4804 in Crohn's Disease (Regional Enteritis) Drug Details:JNJ-4804 is under development for the treatment of ulcerative...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sodium Dichloroacetate in Glioblastoma Multiforme (GBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Sodium Dichloroacetate in Glioblastoma Multiforme (GBM)Drug Details:Sodium dichloroacetate is under development for the treatment of pyruvate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IVX-037 in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.IVX-037 in Adenocarcinoma Of The Gastroesophageal JunctionDrug Details:IVX-037 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Irinotecan Hydrochloride in Neuroblastoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Irinotecan Hydrochloride in Neuroblastoma Drug Details:irinotecan hydrochloride is under development for the treatment of recurrent pediatric solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ranibizumab Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ranibizumab Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration Drug Details: Ranibizumab biosimilar is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Celyvir in Osteosarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Celyvir in Osteosarcoma Drug Details: Celyvir was under investigation for the treatment of refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinengotinib in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinengotinib in Hepatocellular Carcinoma Drug Details: TT-00420 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-202 in Metastatic Renal Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.XTX-202 in Metastatic Renal Cell Carcinoma Drug Details:XTX-202 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CTX-712 in Chronic Myelomonocytic Leukemia (CMML)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CTX-712 in Chronic Myelomonocytic Leukemia (CMML) Drug Details: CTX-712 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Midazolam Hydrochloride in Status Epilepticus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Midazolam Hydrochloride in Status Epilepticus Drug Details:Midazolam (Buccolam) is a benzodiazepine derivative acts as anti-epileptic agent. ...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – S-588410 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.S-588410 in Non-Small Cell Lung CancerDrug Details:S-588410 is under development for the treatment of advanced or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TRPH-222 in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TRPH-222 in Follicular Lymphoma Drug Details:TRPH-222 is under development for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GM-6 in Acute Ischemic Stroke
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GM-6 in Acute Ischemic Stroke Drug Details:GM-6 is under development for the treatment of amyotrophic lateral...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Stenoparib in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Stenoparib in Pancreatic Cancer Drug Details:Stenoparib (E-7449) is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 4SC-205 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. 4SC-205 in Non-Small Cell Lung Cancer Drug Details: 4SC-205 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BCA-101 in Oral Cavity (Mouth) Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BCA-101 in Oral Cavity (Mouth) Cancer Drug Details: BCA-101 is under development for the treatment...
-
Company Profile
![]()
Fusion Pharmaceuticals Inc – Company Profile
Fusion Pharmaceuticals Inc (Fusion Pharmaceuticals) is a clinical-stage biopharmaceutical company which develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059 and FPI-1966. The company’s pipeline products are to treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. Fusion Pharmaceuticals carters its products under brand Keytruda. The company is a spin-off from the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.